Temodal gets expanded label in Europe

Schering-Plough (SGP) said the EMEA approved Temodal temozolomide as a first-line treatment for newly diagnosed glioblastoma multiforme (GBM). The oral imidazotetrazine cytotoxic alkylating agent alre...